Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

Vaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We compared immune responses to the Pfizer/BioNTech mRNA vaccine in solid tumor patients (n=53) on active cytotoxic anti-cancer therapy to a control cohort (n=50) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shroff, Rachna T., Chalasani, Pavani, Wei, Ran, Pennington, Daniel, Quirk, Grace, Schoenle, Marta V., Peyton, Kameron L., Uhrlaub, Jennifer L., Ripperger, Tyler J., Jergović, Mladen, Dalgai, Shelby, Wolf, Alexander, Whitmer, Rebecca, Hammad, Hytham, Carrier, Amy, Scott, Aaron J., Nikolich-Žugich, Janko, Worobey, Michael, Sprissler, Ryan, Dake, Michael, LaFleur, Bonnie J., Bhattacharya, Deepta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132263/
https://www.ncbi.nlm.nih.gov/pubmed/34013289
http://dx.doi.org/10.1101/2021.05.13.21257129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132263/
https://www.ncbi.nlm.nih.gov/pubmed/34013289
http://dx.doi.org/10.1101/2021.05.13.21257129

Ejemplares similares